Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung function (by 4.68% to 5.32%) compared to placebo ...

Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Approval based on global phase 3 program in children demonstrating Dupixent significantly ...

Chicago-based CRISPR technology company Syntax Bio says it has developed tech which automates the slow, manual process of ...

Overview: The demand for programming skills in 2026 centres around versatility, performance, and scalability as companies ramp up AI, cloud, and web services.La ...

State auditors flagged mismanagement and political influence in AICS and AKAP, yet the bicameral committee still approved ...

Boehringer Ingelheim has opened another front in its attack on chronic kidney disease (CKD), offering Rectify Pharmaceuticals up to $448 million to partner on a preclinical program.

Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

The daily burden for those living with type 1 diabetes is constant, and Breakthrough T1D remains focused on accelerating the path to cures for the disease,” said Nicholas Mamrak, Ph.D., scientist at ...

As the global population ages, 2025 has delivered a remarkable wave of new research aimed at supporting healthier brains in ...

A new study led by scientists at the Perception Dynamics Institute and the University of California San Diego demonstrates ...

Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2 -- Affecting up to 100,000 people in the U.S. and up to 5.6 ...